AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Update on UK Availability of AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division